MCID: LMY004
MIFTS: 62

Leiomyosarcoma

Categories: Cancer diseases, Muscle diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Leiomyosarcoma

MalaCards integrated aliases for Leiomyosarcoma:

Name: Leiomyosarcoma 12 73 20 58 54 6 44 15 17 70
Leiomyosarcomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1967
MeSH 44 D007890
NCIt 50 C3158
SNOMED-CT 67 443719001
MESH via Orphanet 45 D007890
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 71 C0023269
Orphanet 58 ORPHA64720
UMLS 70 C0023269

Summaries for Leiomyosarcoma

GARD : 20 Leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells. Leiomyosarcoma is a type of sarcoma. It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. The exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. It is most often found in the uterus or abdomen.

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to lung leiomyosarcoma and inflammatory leiomyosarcoma. An important gene associated with Leiomyosarcoma is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Dacarbazine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include smooth muscle, uterus and liver, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Disease Ontology : 12 A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : 73 Leiomyosarcoma, is a malignant (cancerous) smooth muscle tumor. A benign tumor originating from the same... more...

Related Diseases for Leiomyosarcoma

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 916)
# Related Disease Score Top Affiliating Genes
1 lung leiomyosarcoma 32.7 MYOG KIT CHEK2
2 inflammatory leiomyosarcoma 32.6 MYOG DES
3 liver leiomyosarcoma 32.6 WT1 KIT ENO2
4 uterus leiomyosarcoma 32.5 PGR MYOG KIT ENO2
5 colon leiomyosarcoma 32.5 WT1 PDGFRA KIT
6 gallbladder leiomyosarcoma 32.5 MB KIT
7 cutaneous leiomyosarcoma 32.4 VIM MUC1 FH DES ACTC1
8 breast leiomyosarcoma 32.4 MB KIT ENO2
9 gastric leiomyosarcoma 32.4 PDGFRA KIT
10 epithelioid leiomyosarcoma 32.2 VIM SERPINA3 PGR MUC1 MB ENO2
11 rare tumor 32.0 KIT DES ACTC1
12 vascular cancer 31.9 SERPINA3 PDGFRB MYOG KIT
13 myoma 31.2 PGR KIT FH
14 malignant fibrous histiocytoma 31.1 VIM SERPINA3 PDGFRB MYOG MUC1 MDM2
15 bilateral retinoblastoma 30.9 MYOG MB DES
16 fibrous histiocytoma 30.9 VIM SERPINA3 KIT ENO2 DES ACTC1
17 secretory meningioma 30.9 VIM SERPINA3 MUC1
18 intravenous leiomyomatosis 30.8 PGR DES
19 bizarre leiomyoma 30.8 PGR FH ACTC1
20 fibrosarcoma 30.8 VIM PDGFRA KIT DES ACTC1
21 spindle cell sarcoma 30.8 VIM SERPINA3 MYOG MUC1 MDM2 KIT
22 malignant mesenchymoma 30.8 SERPINA3 MYOG MDM2 MB DES
23 leiomyoma 30.8 VIM S100A1 PGR PDGFRA KIT IGF2
24 mesenchymal cell neoplasm 30.7 SERPINA3 PDGFRB PDGFRA MYOG KIT
25 chondroma 30.7 S100A1 PDGFRA KIT ACTC1
26 smooth muscle tumor 30.7 VIM SERPINA3 S100A1 PGR KIT IGF2
27 fibroma 30.7 VIM SERPINA3 S100A1 DES ACTC1
28 leiomyomatosis 30.7 WT1 PGR KIT FH
29 intracranial meningioma 30.6 PGR IGF2
30 liposarcoma 30.6 VIM PDGFRA MYOG MDM2 MB DES
31 pneumothorax 30.6 VIM PGR MUC1
32 adenocarcinoma 30.6 PDGFRB MUC1 MDM2 KIT CDK4
33 angiosarcoma 30.6 VIM MUC1 MDM2 KIT
34 carcinosarcoma 30.5 VIM S100A1 PGR MUC1 MB KIT
35 pleomorphic lipoma 30.5 SERPINA3 PGR MDM2 CDK4
36 myofibroma 30.5 SERPINA3 S100A1 PDGFRB MB DES
37 heart sarcoma 30.5 MYOG MDM2 KIT
38 osteogenic sarcoma 30.5 WT1 MDM2 IGF2 CHEK2 CDK4
39 benign breast phyllodes tumor 30.5 VIM PGR KIT
40 prostate sarcoma 30.4 PGR MYOG
41 lipomatosis, multiple 30.4 SERPINA3 MDM2 KIT DES CDK4
42 angiomyolipoma 30.4 VIM S100A1 PGR KIT DES ACTC1
43 vagina sarcoma 30.3 VIM PGR MYOG KIT
44 sarcoma 30.3 WT1 VIM PDGFRA MYOG MUC1 MDM2
45 sarcomatoid renal cell carcinoma 30.3 S100A1 MUC1 MDM2 KIT
46 lymphangioma 30.3 VIM SERPINA3 ACTC1
47 gallbladder sarcoma 30.3 MYOG DES
48 cystadenoma 30.3 SERPINA3 PGR MUC1 FH
49 gastric leiomyoma 30.3 PDGFRA KIT FH
50 endometrial stromal sarcoma 30.3 VIM PGR PDGFRB PDGFRA MB KIT

Graphical network of the top 20 diseases related to Leiomyosarcoma:



Diseases related to Leiomyosarcoma

Symptoms & Phenotypes for Leiomyosarcoma

GenomeRNAi Phenotypes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.23 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.23 CDK4 KIT
3 Decreased substrate adherent cell growth GR00193-A-3 9.23 CDK4 CHEK2
4 Decreased substrate adherent cell growth GR00193-A-4 9.23 CDK4 CHEK2 KIT
5 Decreased cell viability after pRB stimulation GR00230-A-1 8.65 PDGFRB

MGI Mouse Phenotypes related to Leiomyosarcoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 ACTC1 CDK4 CHEK2 DES ENO2 FH
2 homeostasis/metabolism MP:0005376 10.41 ACTC1 CDK4 CHEK2 DES FH IGF2
3 cardiovascular system MP:0005385 10.39 ACTC1 CDK4 CHEK2 DES IGF2 KIT
4 behavior/neurological MP:0005386 10.37 CDK4 DES ENO2 IGF2 KIT MDM2
5 mortality/aging MP:0010768 10.31 ACTC1 CDK4 CHEK2 DES FH IGF2
6 embryo MP:0005380 10.29 ACTC1 CDK4 IGF2 KIT MB MDM2
7 muscle MP:0005369 10.28 ACTC1 CAPN6 CDK4 DES IGF2 KIT
8 hematopoietic system MP:0005397 10.27 ACTC1 CDK4 CHEK2 IGF2 KIT MB
9 craniofacial MP:0005382 10.18 ACTC1 CAPN6 CDK4 ENO2 IGF2 KIT
10 integument MP:0010771 10.11 CDK4 IGF2 KIT MDM2 MYOG PDGFRA
11 normal MP:0002873 10 ACTC1 CDK4 KIT MDM2 MYOG PDGFRA
12 neoplasm MP:0002006 9.91 CDK4 CHEK2 KIT MDM2 PDGFRA PGR
13 no phenotypic analysis MP:0003012 9.87 IGF2 KIT MDM2 MYOG PDGFRA PGR
14 renal/urinary system MP:0005367 9.76 CDK4 FH IGF2 KIT MDM2 PDGFRA
15 reproductive system MP:0005389 9.65 CDK4 CHEK2 IGF2 KIT MDM2 PDGFRA
16 respiratory system MP:0005388 9.28 ENO2 IGF2 KIT MB MYOG PDGFRA

Drugs & Therapeutics for Leiomyosarcoma

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166 2942
2
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
3
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
4
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
5
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Gemcitabine Approved Phase 3 95058-81-4 60750
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
10
Lenograstim Approved, Investigational Phase 3 135968-09-1
11
Bevacizumab Approved, Investigational Phase 3 216974-75-3
12
Molgramostim Investigational Phase 3 99283-10-0
13
Isophosphamide mustard Phase 2, Phase 3 100427
14 Antibiotics, Antitubercular Phase 3
15
Liposomal doxorubicin Phase 3 31703
16 Anti-Bacterial Agents Phase 3
17 Anti-Infective Agents Phase 3
18 Immunosuppressive Agents Phase 3
19 Immunologic Factors Phase 3
20 Antineoplastic Agents, Immunological Phase 3
21 Antibodies Phase 3
22 Immunoglobulins, Intravenous Phase 3
23 Immunoglobulins Phase 3
24 Antibodies, Monoclonal Phase 3
25 Antiviral Agents Phase 3
26 Antimetabolites Phase 3
27 Tubulin Modulators Phase 3
28 Antimitotic Agents Phase 3
29 Adjuvants, Immunologic Phase 3
30 Angiogenesis Inhibitors Phase 3
31 Immunoglobulin G Phase 3
32 Mitogens Phase 3
33 Endothelial Growth Factors Phase 3
34
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
35
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
36
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
37
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
38
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
39
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
40
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
41
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
42
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
45
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
46
Lenvatinib Approved, Investigational Phase 1, Phase 2 417716-92-8
47
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
48
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
49
Durvalumab Approved, Investigational Phase 2 1428935-60-7
50
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Randomised Phase III Multicentric Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin in Non-progressive Patients Versus Doxorubicine Alone as First-line Therapy in Patients With Metastatic or Unresectable Leiomyosarcoma (Uterine or Soft Tissue) Unknown status NCT02997358 Phase 3 Doxorubicin;Trabectedin
2 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
4 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
5 Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma Recruiting NCT04307277 Phase 3 Standard of care + chemotherapy
6 A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL3818;Dacarbazine;AL3818 or placebo
7 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Recruiting NCT04031677 Phase 3 Preoperative chemotherapy
8 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
9 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
10 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma Terminated NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
11 A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
12 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
13 GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
14 A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
15 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
16 Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
17 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
18 A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET Completed NCT00668148 Phase 2
19 Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas Completed NCT01442662 Phase 2 pazopanib + gemcitabine
20 A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas Completed NCT00379145 Phase 2 trabectedin
21 Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
22 A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma Completed NCT00093080 Phase 2 ridaforolimus
23 Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
24 A Phase II Study of Mocetinostat Administered With Gemcitabine for Patients With Metastatic Leiomyosarcoma With Progression or Relapse Following Prior Treatment With Gemcitabine-Containing Therapy Completed NCT02303262 Phase 2 Mocetinostat;Gemcitabine
25 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
26 A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
27 Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2 letrozole
28 A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
29 A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
30 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
31 A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
32 A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma Completed NCT00310518 Phase 2 ARQ 501
33 A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
34 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01220609 Phase 2 Ixabepilone
35 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
36 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00025220 Phase 2 Thalidomide
37 Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
38 A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
39 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
40 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
41 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
42 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
43 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
44 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
45 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
46 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
47 Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
48 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
49 Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
50 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Genetic Tests for Leiomyosarcoma

Anatomical Context for Leiomyosarcoma

MalaCards organs/tissues related to Leiomyosarcoma:

40
Smooth Muscle, Uterus, Liver, Bone, Breast, Small Intestine, Kidney

Publications for Leiomyosarcoma

Articles related to Leiomyosarcoma:

(show top 50) (show all 10355)
# Title Authors PMID Year
1
Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. 61 6
28514723 2017
2
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. 54 61
20081808 2010
3
Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value. 61 54
20437637 2010
4
Axillary and perianal leiomyosarcoma: report of two cases. 54 61
20495760 2010
5
WT-1 expression in gastrointestinal stromal tumours. 61 54
20025481 2010
6
A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. 54 61
19734847 2009
7
Gastric leiomyosarcoma manifesting peculiar findings: radiological-pathological correlation. 61 54
19432672 2009
8
Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. 61 54
18941404 2009
9
[Acute abdomen for perforated gastrointestinal stromal tumor (GIST). A case report]. 61 54
19537128 2009
10
Absence of fumarate hydratase mutation in a family with cutaneous leiomyosarcoma and renal cancer. 61 54
18986479 2008
11
Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. 61 54
18778186 2008
12
[Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. 54 61
18565690 2008
13
Clinicopathological characteristics of gastrointestinal mesenchymal tumors and diagnostic value of endoscopic ultrasonography. 61 54
18505417 2008
14
Recurrent nodule on the nasal columella: a good reason to re-biopsy. 61 54
18613884 2008
15
Breast metastasis from uterine leiomyosarcoma diagnosed by fine needle aspiration: a case report. 61 54
18702371 2008
16
Cytoplasmic overexpression of WT-1 in gastrointestinal stromal tumor and other soft tissue tumors. 54 61
18528287 2008
17
Immunohistochemical distinction of cutaneous spindle cell carcinoma. 61 54
18496422 2008
18
A rare tumor in the adrenal region: neuron-specific enolase (NSE)-producing leiomyosarcoma in an elderly hypertensive patient. 54 61
18250540 2008
19
[Adult prostate sarcoma: a report of 6 cases with clinical analysis]. 61 54
17725305 2007
20
Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells. 54 61
17368523 2007
21
Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis. 61 54
17550381 2007
22
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. 61 54
17396140 2007
23
Comparative study using rabbit-derived polyclonal, mouse-derived monoclonal, and rabbit-derived monoclonal antibodies for KIT immunostaining in GIST and other tumors. 54 61
17316415 2007
24
PDGFR-alpha as a potential therapeutic target in uterine sarcomas. 54 61
17049587 2007
25
C-kit protein expression in uterine and ovarian mesenchymal tumours. 54 61
17367465 2007
26
Esophageal mesenchymal tumors: endoscopy, pathology and immunohistochemistry. 54 61
17278201 2007
27
Nestin expression as a new marker in malignant peripheral nerve sheath tumors. 54 61
17300669 2007
28
Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis. 61 54
17291261 2007
29
Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors. 54 61
17129677 2007
30
[Gastrointestinal mesenchymal tumors: a clinical pathologic and immunohistochemical study of 210 cases]. 61 54
17253165 2007
31
A case of cutaneous leiomyosarcoma with overexpression of KIT: do CD117 (KIT)-positive primary gastrointestinal stromal tumours of the skin exist? 54 61
16634920 2006
32
Gastrointestinal stromal tumors: differential diagnosis. 61 54
17193824 2006
33
[Extragastrointestinal stromal tumors: a report of 4 cases]. 61 54
16472759 2006
34
Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. 54 61
16625090 2006
35
No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. 61 54
15949892 2006
36
Calretinin expression in tumors of adipose tissue. 54 61
16613326 2006
37
Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. 61 54
16330948 2006
38
The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. 61 54
15992918 2005
39
Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. 54 61
16160478 2005
40
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 61 54
16082245 2005
41
Primary osteosarcoma of the thoracic spine: report of an unusual elderly patient with autopsy findings. 54 61
15753962 2005
42
INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. 54 61
15761491 2005
43
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. 61 54
15894930 2005
44
Carcinosarcoma of the liver: a case report and review of the literature. 61 54
15913431 2005
45
Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects. 61 54
16033061 2005
46
So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity. 61 54
15864383 2005
47
[Malignant fibrous histiocytoma: pleomorphic sarcoma NOS or pleomorphic fibrosarcoma]. 61 54
15702318 2005
48
[Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. 54 61
15774214 2005
49
[Gastrointestinal stromal tumor: a clinicopathological study of 74 cases]. 61 54
15796874 2005
50
Intimal sarcoma of the pulmonary artery: report of an autopsy case. 54 61
16136754 2005

Variations for Leiomyosarcoma

ClinVar genetic disease variations for Leiomyosarcoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs) Deletion Pathogenic 128042 rs555607708 GRCh37: 22:29091857-29091857
GRCh38: 22:28695869-28695869

Cosmic variations for Leiomyosarcoma:

9 (show top 50) (show all 2128)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149325379 ZFHX3 soft tissue,smooth muscle,leiomyosarcoma,NS c.2513A>G p.N838S 16:72957633-72957633 3
2 COSM102044775 ZFHX3 soft tissue,smooth muscle,leiomyosarcoma,NS c.-23-6668A>G p.? 16:72957633-72957633 3
3 COSM87293976 ZFHX3 soft tissue,smooth muscle,leiomyosarcoma,NS c.2513A>G p.N838S 16:72957633-72957633 3
4 COSM104236272 XPO1 soft tissue,smooth muscle,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 3
5 COSM101976974 XPO1 soft tissue,smooth muscle,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 3
6 COSM104882801 XPO1 soft tissue,smooth muscle,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 3
7 COSM148791748 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
8 COSM147982566 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
9 COSM151103730 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1122C>A p.N374K 9:132911064-132911064 3
10 COSM151874979 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
11 COSM102541613 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.*317C>A p.? 9:132911064-132911064 3
12 COSM150523552 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
13 COSM148126195 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
14 COSM149038920 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
15 COSM150677027 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
16 COSM150536467 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.926C>A p.T309N 9:132911064-132911064 3
17 COSM111040244 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
18 COSM148033864 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
19 COSM133086425 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.926C>A p.T309N 9:132911064-132911064 3
20 COSM151895912 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
21 COSM85719005 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
22 COSM151333783 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
23 COSM144100083 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.331T>G p.F111V 17:7673812-7673812 3
24 COSM106055950 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.374C>A p.T125K 17:7675995-7675995 3
25 COSM87912584 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.376-1G>A p.? 17:7675237-7675237 3
26 COSM105657416 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.641A>C p.H214P 17:7674890-7674890 3
27 COSM105620642 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 17:7674221-7674221 3
28 COSM105625281 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.782+402G>A p.? 17:7673779-7673779 3
29 COSM143945794 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.-51G>A p.? 17:7675185-7675185 3
30 COSM143971570 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.164A>C p.H55P 17:7674890-7674890 3
31 COSM122279858 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.77G>A p.R26H 17:7675139-7675139 3
32 COSM143370705 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.542A>G p.Y181C 17:7674872-7674872 3
33 COSM142837551 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 17:7674221-7674221 3
34 COSM144659750 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.356G>C p.R119P 17:7675139-7675139 3
35 COSM142568491 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.356G>A p.R119H 17:7675139-7675139 3
36 COSM143944281 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.83-1G>A p.? 17:7674972-7674972 3
37 COSM143167912 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.-104A>T p.? 17:7675238-7675238 3
38 COSM121897862 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.317G>T p.C106F 17:7674250-7674250 3
39 COSM142561826 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.521G>A p.R174Q 17:7674893-7674893 3
40 COSM142560355 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.334C>T p.P112S 17:7675161-7675161 3
41 COSM145036361 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.596G>T p.C199F 17:7674250-7674250 3
42 COSM145034453 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.706T>C p.C236R 17:7673797-7673797 3
43 COSM143162643 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.308G>T p.G103V 17:7673835-7673835 3
44 COSM121893200 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.121G>C p.V41L 17:7675095-7675095 3
45 COSM123055238 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.179A>T p.Q60L 17:7674956-7674956 3
46 COSM122734176 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.347G>A p.R116Q 17:7674220-7674220 3
47 COSM93183630 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.743G>A p.R248Q 17:7674220-7674220 3
48 COSM144087106 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.266G>A p.R89Q 17:7674220-7674220 3
49 COSM144652260 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.464T>C p.L155P 17:7674950-7674950 3
50 COSM144658526 TP53 soft tissue,smooth muscle,leiomyoma,NS c.400G>T p.V134L 17:7675095-7675095 3

Copy number variations for Leiomyosarcoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 102985 16 58400001 69400000 Loss Leiomyosarcoma

Expression for Leiomyosarcoma

Search GEO for disease gene expression data for Leiomyosarcoma.

Pathways for Leiomyosarcoma

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 VIM PDGFRB PDGFRA MUC1 MDM2 KIT
2
Show member pathways
12.81 PDGFRB PDGFRA MDM2 KIT IGF2 CDK4
3 12.42 PDGFRB PDGFRA MDM2 KIT IGF2 FH
4
Show member pathways
12.08 PDGFRB PDGFRA MDM2 CHEK2 CAPN6
5 11.56 VIM DES ACTC1
6 11.53 PDGFRB PDGFRA KIT
7
Show member pathways
11.37 PDGFRB PDGFRA KIT
8 11.3 MDM2 CHEK2 CDK4
9 11.25 MDM2 CHEK2 CDK4
10 11.07 PDGFRB PDGFRA MDM2 IGF2 CDK4
11
Show member pathways
11.03 PDGFRB PDGFRA KIT
12 10.98 PDGFRA KIT IGF2 ACTC1
13 10.75 VIM PDGFRB PDGFRA KIT IGF2 DES

GO Terms for Leiomyosarcoma

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 WT1 VIM SERPINA3 S100A1 PGR PDGFRB
2 cytoplasm GO:0005737 9.53 WT1 VIM S100A1 PGR PDGFRB PDGFRA

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 WT1 VIM MDM2 KIT ACTC1
2 positive regulation of cell proliferation GO:0008284 9.88 PDGFRB PDGFRA MDM2 KIT IGF2 CDK4
3 positive regulation of protein kinase B signaling GO:0051897 9.81 PDGFRB PDGFRA KIT IGF2
4 protein autophosphorylation GO:0046777 9.8 PDGFRB PDGFRA KIT CHEK2
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 PDGFRB PDGFRA KIT
6 response to toxic substance GO:0009636 9.76 PDGFRB MDM2 CDK4
7 cell chemotaxis GO:0060326 9.75 PDGFRB PDGFRA KIT
8 positive regulation of kinase activity GO:0033674 9.73 PDGFRB PDGFRA KIT
9 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.7 MUC1 MDM2 CHEK2
10 positive regulation of fibroblast proliferation GO:0048146 9.65 PDGFRB PDGFRA CDK4
11 muscle filament sliding GO:0030049 9.61 VIM DES ACTC1
12 metanephric mesenchyme development GO:0072075 9.55 WT1 PDGFRB
13 retina vasculature development in camera-type eye GO:0061298 9.54 PDGFRB PDGFRA
14 metanephric S-shaped body morphogenesis GO:0072284 9.46 WT1 PDGFRB
15 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.43 PDGFRB PDGFRA KIT
16 metanephric glomerular capillary formation GO:0072277 9.37 PDGFRB PDGFRA
17 negative regulation of cell cycle arrest GO:0071157 9.33 MDM2 CHEK2 CDK4
18 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.32 PDGFRB PDGFRA
19 positive regulation of phospholipase C activity GO:0010863 9.13 PDGFRB PDGFRA KIT
20 cardiac myofibril assembly GO:0055003 8.8 PDGFRB PDGFRA ACTC1

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.65 PDGFRB PDGFRA KIT CHEK2 CDK4
2 platelet-derived growth factor binding GO:0048407 9.16 PDGFRB PDGFRA
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 PDGFRB PDGFRA KIT
4 vascular endothelial growth factor binding GO:0038085 8.62 PDGFRB PDGFRA

Sources for Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....